JP2023523622A5 - - Google Patents

Info

Publication number
JP2023523622A5
JP2023523622A5 JP2022565707A JP2022565707A JP2023523622A5 JP 2023523622 A5 JP2023523622 A5 JP 2023523622A5 JP 2022565707 A JP2022565707 A JP 2022565707A JP 2022565707 A JP2022565707 A JP 2022565707A JP 2023523622 A5 JP2023523622 A5 JP 2023523622A5
Authority
JP
Japan
Prior art keywords
optionally
nucleic acid
transposase
approximately
myotis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022565707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523622A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/030007 external-priority patent/WO2021222654A1/en
Publication of JP2023523622A publication Critical patent/JP2023523622A/ja
Publication of JP2023523622A5 publication Critical patent/JP2023523622A5/ja
Pending legal-status Critical Current

Links

JP2022565707A 2020-04-29 2021-04-29 遺伝性黄斑変性症の治療のための組成物及び方法 Pending JP2023523622A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017442P 2020-04-29 2020-04-29
US63/017,442 2020-04-29
PCT/US2021/030007 WO2021222654A1 (en) 2020-04-29 2021-04-29 Compositions and methods for treatment of inherited macular degeneration

Publications (2)

Publication Number Publication Date
JP2023523622A JP2023523622A (ja) 2023-06-06
JP2023523622A5 true JP2023523622A5 (https=) 2024-05-15

Family

ID=78332210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565707A Pending JP2023523622A (ja) 2020-04-29 2021-04-29 遺伝性黄斑変性症の治療のための組成物及び方法

Country Status (9)

Country Link
US (1) US20230193319A1 (https=)
EP (1) EP4142796A4 (https=)
JP (1) JP2023523622A (https=)
KR (1) KR20230004573A (https=)
CN (1) CN115461082A (https=)
AU (1) AU2021265838A1 (https=)
CA (1) CA3175197A1 (https=)
IL (1) IL297718A (https=)
WO (1) WO2021222654A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146798A4 (en) 2020-05-04 2025-02-12 Saliogen Therapeutics, Inc. TRANSPOSITION-BASED THERAPIES
WO2023160454A1 (zh) * 2022-02-25 2023-08-31 北京中因科技有限公司 表达盒组合及其应用
EP4511496A2 (en) * 2022-04-18 2025-02-26 Abeona Therapeutics Inc. Compositions and methods for treating dominant optic atrophy and x-linked retinoschisis
CN120230798A (zh) * 2023-12-29 2025-07-01 上海朗昇生物科技有限公司 用于视网膜基因递送的重组腺相关病毒载体及其应用
WO2025147466A1 (en) * 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. Treatment for asymptomatic stargardt disease patients
WO2025188836A1 (en) * 2024-03-05 2025-09-12 Saliogen Therapeutics, Inc. Compositions and methods of using gene coding for treating ocular disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309487B2 (en) * 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
US7943374B2 (en) * 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
CN101873852A (zh) * 2007-09-27 2010-10-27 锐视医药公司 治疗视黄醇相关性疾病的方法和化合物
US20090214478A1 (en) * 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
EP2401376A4 (en) * 2009-02-25 2012-11-28 Univ Johns Hopkins TRANSPOSON PIGGYBAC VARIANTS AND METHODS OF USE
US20150141320A1 (en) * 2012-05-16 2015-05-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
AU2014255665B2 (en) * 2013-04-18 2018-08-02 Fondazione Telethon Effective delivery of large genes by dual AAV vectors
AU2015234242B2 (en) * 2014-03-21 2020-09-24 Children's Medical Research Institute Stable gene transfer to proliferating cells
JP7036723B2 (ja) * 2015-12-14 2022-03-15 コールド スプリング ハーバー ラボラトリー 眼疾患の処置のための組成物および方法
EP3687580A1 (en) * 2017-09-27 2020-08-05 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
WO2020077360A1 (en) * 2018-10-12 2020-04-16 Poseida Therapeutics, Inc. Hematopoietic stem cell compositions, methods of making and method of use

Similar Documents

Publication Publication Date Title
JP2023523622A5 (https=)
US20220387560A1 (en) Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
US20230039928A1 (en) Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease
CA2904164C (en) Mir-204 and mir-211 and uses thereof
CN114829598A (zh) 一种治疗Usher综合征的方法和其组合物
JP2022546597A (ja) 閉端ｄｎａおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法
CN114040974B (zh) 用于高效rna反式剪接的三螺旋终止子
CN108350446A (zh) 基于crispr/cas9的治疗
JP2022521764A (ja) Ｒｈｏ関連常染色体優性網膜色素変性症（ａｄｒｐ）を治療するためのｃｒｉｓｐｒ／ｒｎａ誘導ヌクレアーゼ関連の方法及び組成物
JP2004532844A (ja) イオントホレシスのステップを含む方法により送達されるキメラオリゴヌクレオチドでの遺伝子療法
JP2025020293A (ja) アンチセンスオリゴヌクレオチドは、ａｂｃａ４の異常スプライシングをレスキューする
US20220305142A1 (en) Ocular delivery of therapeutic agents
JP7334346B2 (ja) ロドプシン転写体に特異的なトランススプライシングリボザイム及びその用途
US20260007773A1 (en) Ocular vectors and uses thereof
WO2024088175A1 (zh) 基因编辑系统及其应用
CN120641085A (zh) 包含核酸、可电离脂质、固醇、脂质锚定聚合物和辅助脂质的脂质纳米颗粒、其用途
CN118028368A (zh) 靶向5’utr的不依赖于突变的基因敲入治疗
CN116334141A (zh) 基于基因编辑的RHO-R135W-adRP基因编辑药物
RU2810907C1 (ru) Система направленного изменения сплайсинга в гене MARK2
JP2025534371A (ja) Ｏｐａ１遺伝子変異に関連付けられる疾患を治療するためのｏｐａ１プレメッセンジャーｒｎａのトランススプライシングによる療法
AU2024256497A1 (en) Genome editing methods and constructs
WO2024110770A1 (en) A new promoter for retinal pigment epithelium (rpe) targeted gene therapy
WO2026039524A1 (en) Msh3 modulatory molecules
Cardoso et al. Nonviral Therapeutic Approaches for Modulation of Gene Expression: Nanotechnological Strategies to Overcome Biological Challenges
JP2025539859A (ja) ベクターベースの治療のためのコンプスタチンアナログ